Request My Consultation

How Can We Help?

Quick Contact Form

Send My Info

Recent Posts in Defective and Dangerous Drugs Category

  • FDA Proposes A Change to Generic Drug Labeling

    || 19-Nov-2013

    Federal regulators have just issued a proposed rule change that would enable the makers of generic drugs to update drug labels when they receive safety information related to their medications. Under current regulations, this is restricted for generic drug makers, who must ensure their labels contain the same information as the related brand version. Approval of the U.S. Food and Drug ...
    Continue Reading
  • Johnson & Johnson Agrees to Multi-Billion Dollar Risperdal Settlement

    || 13-Nov-2013

    In the largest settlement for one drug, Janssen Pharmaceuticals pleaded guilty to misbranding its antipsychotic medication, Risperdal, as part of a massive $2.2 billion settlement with the Department of Justice. Janssen is a unit of Johnson & Johnson. Janssen entered the guilty plea to one misdemeanor at an hour-long hearing before U.S. District Judge Timothy Savage in Philadelphia, ...
    Continue Reading
  • Serious Blood Clot Reactions Seen in Iclusig Leukemia Treatment

    || 8-Nov-2013

    Leukemia drug Iclusig (ponatinib) is the focus of a U.S. Food and Drug Administration (FDA) Drug Safety Alert over its association with serious blood clots. Ariad Pharmaceuticals, Inc. manufactures Iclusig. The FDA has asked Ariad Pharmaceuticals to cease marketing of the dangerous drug Iclusig after receiving reports of serious blood clots in patients' veins and arteries. The drug received ...
    Continue Reading